Provided by Tiger Trade Technology Pte. Ltd.

Cumberland Pharmaceuticals

3.06
+0.23008.13%
Volume:17.30K
Turnover:50.73K
Market Cap:45.77M
PE:-16.11
High:3.06
Open:2.84
Low:2.84
Close:2.83
52wk High:6.27
52wk Low:1.85
Shares:14.96M
Float Shares:7.97M
Volume Ratio:0.24
T/O Rate:0.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1900
EPS(LYR):-0.1909
ROE:-12.17%
ROA:-2.29%
PB:1.84
PE(LYR):-16.03

Loading ...

Cumberland Pharmaceuticals Inc. Announces Annual Shareholder Meeting

Reuters
·
Mar 10

Cumberland Pharma Q4 net revenues rise 31% to USD 13.7 million

Reuters
·
Mar 04

Cumberland Q4 Adj. EPS $(0.01) Up From $(0.02) YoY, Sales $13.679M Up From $10.436M YoY

Benzinga
·
Mar 04

Cumberland Pharmaceuticals Q4 Revenue USD 13.7 Million

THOMSON REUTERS
·
Mar 04

Cumberland Pharmaceuticals launches U.S. promotion of Talicia

Reuters
·
Feb 25

Cumberland Pharmaceuticals Inc. published an update to their financial calendar

Reuters
·
Feb 25

Cumberland Pharmaceuticals Wins Fast Track for Ifetroban

TIPRANKS
·
Feb 05

BUZZ-Cumberland jumps as heart drug for muscle‑wasting disease gets FDA's fast-track tag

Reuters
·
Feb 04

Cumberland receives fast track designation for DMD oral therapy from FDA

TIPRANKS
·
Feb 04

Cumberland Pharmaceuticals Wins FDA Fast Track for Ifetroban in Duchenne Muscular Dystrophy

Reuters
·
Feb 04

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for Its Ifetroban Duchenne Muscular Dystrophy Program

THOMSON REUTERS
·
Feb 04

Cumberland Pharmaceuticals Leads 3 Promising Penny Stocks

Simply Wall St.
·
Dec 17, 2025

Cumberland Pharmaceuticals Amends Credit Agreement With Pinnacle Bank, Extends Maturity to 2027

Reuters
·
Nov 24, 2025

Cumberland Pharmaceuticals Reports Revenue Growth and Strategic Expansions

TIPRANKS
·
Nov 05, 2025

Cumberland Pharmaceuticals' Q3 revenue declines to $8.3 mln

Reuters
·
Nov 05, 2025

Cumberland Q3 Adj. EPS $(0.06) Down From $(0.02) YoY, Sales $8.292M Down From $9.086M YoY

Benzinga
·
Nov 05, 2025

Cumberland Pharmaceuticals reports $30.8 million year-to-date revenue, 12% increase

Reuters
·
Nov 05, 2025

Cumberland Pharmaceuticals Q3 Operating Expenses USD 10.3 Million

THOMSON REUTERS
·
Nov 05, 2025

Cumberland Pharmaceuticals Reports 12% Year-to-Date Revenue Growth

THOMSON REUTERS
·
Nov 05, 2025

Cumberland Pharmaceuticals Inc. to Release Q3 2025 Financial Results

Reuters
·
Oct 29, 2025